Trial Profile
Selective Estrogen Receptor Modulators - Adjunctive Treatment for Negative and Cognitive Symptoms of Schizophrenia in Postmenopausal Women
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Sep 2019
Price :
$35
*
At a glance
- Drugs Raloxifene (Primary)
- Indications Postmenopause; Schizophrenia
- Focus Therapeutic Use
- 22 Sep 2027 Inclusion criteria mentions "Outpatient or inpatient" so I have not indexed it in segments.
- 04 Sep 2019 Status changed from recruiting to completed.
- 24 Dec 2018 Status changed from not yet recruiting to recruiting.